Literature DB >> 22631861

Interventions to increase enrollment in a large multicenter phase 3 trial of carotid stenting vs. endarterectomy.

Mary E Longbottom1, Jamie N Roberts, Meelee Tom, Susan E Hughes, Virginia J Howard, Alice J Sheffet, James F Meschia, Thomas G Brott.   

Abstract

BACKGROUND: Randomized clinical trials often encounter slow enrollment. Failing to meet sample size requirements has scientific, financial, and ethical implications. AIMS: We report interventions used to accelerate recruitment in a large multicenter clinical trial that was not meeting prespecified enrollment commitments.
METHODS: The Carotid Revascularization Endarterectomy vs. Stenting Trial began randomization in December 2000. To accelerate enrollment, multiple recruitment tactics were initiated, which included expanding the number of sites, hiring a recruitment director (May 2003), broadening eligibility criteria (April 2005), branding with a study logo, Web site, and recruitment materials, increasing site visits by study leadership, sending e-mails to the site teams after every enrollment, distributing electronic newsletters, and implementing investigator and coordinator conferences.
RESULTS: From December 2000 through May 2003, 14 sites became active (54 patients randomized), from June 2003 through April 2005, 44 sites were added (404 patients randomized), and from May 2005 through July 2008, 54 sites were added (2044 patients randomized). During these time intervals, the number of patients enrolled per site per year was 1·5, 3·6, and 5·6. For the single years 2004 to 2008, the mean monthly randomization rates per year were 19·7, 38·1, 56·4, 53·0, and 54·7 (annualized), respectively. Enrollment was highest after recruitment tactics were implemented: 677 patients in 2006, 636 in 2007, and 657 in 2008 (annualized). The prespecified sample size of 2502 patients, 47% asymptomatic, was accomplished on July 2008.
CONCLUSIONS: Aggressive recruitment tactics and investment in a full-time recruitment director who can lead implementation may be effective in accelerating recruitment in multicenter trials.
© 2012 The Authors. International Journal of Stroke © 2012 World Stroke Organization.

Entities:  

Mesh:

Year:  2012        PMID: 22631861      PMCID: PMC3399984          DOI: 10.1111/j.1747-4949.2012.00833.x

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  17 in total

1.  How to do it. Organise a multicentre trial.

Authors:  C Warlow
Journal:  BMJ       Date:  1990-01-20

Review 2.  Efficient management of randomised controlled trials: nature or nurture.

Authors:  B Farrell
Journal:  BMJ       Date:  1998-10-31

3.  The challenges of intracranial revascularization for stroke prevention.

Authors:  Joseph P Broderick
Journal:  N Engl J Med       Date:  2011-09-07       Impact factor: 91.245

Review 4.  Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study.

Authors:  M K Campbell; C Snowdon; D Francis; D Elbourne; A M McDonald; R Knight; V Entwistle; J Garcia; I Roberts; A Grant; A Grant
Journal:  Health Technol Assess       Date:  2007-11       Impact factor: 4.014

5.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

6.  Design of the Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST).

Authors:  A J Sheffet; G Roubin; G Howard; V Howard; W Moore; J F Meschia; R W Hobson; T G Brott
Journal:  Int J Stroke       Date:  2010-02       Impact factor: 5.266

7.  Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial.

Authors:  A Halliday; A Mansfield; J Marro; C Peto; R Peto; J Potter; D Thomas
Journal:  Lancet       Date:  2004-05-08       Impact factor: 79.321

8.  Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.

Authors: 
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

9.  The continuing unethical conduct of underpowered clinical trials.

Authors:  Scott D Halpern; Jason H T Karlawish; Jesse A Berlin
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

10.  Marketing and clinical trials: a case study.

Authors:  David Francis; Ian Roberts; Diana R Elbourne; Haleema Shakur; Rosemary C Knight; Jo Garcia; Claire Snowdon; Vikki A Entwistle; Alison M McDonald; Adrian M Grant; Marion K Campbell
Journal:  Trials       Date:  2007-11-20       Impact factor: 2.279

View more
  5 in total

1.  Surpassing the Target: How a Recruitment Campaign Transformed the Participant Accrual Trajectory in the Epilepsy Phenome/Genome Project.

Authors:  Kathleen McGovern; Catharine Freyer Karn; Kristen Fox
Journal:  Clin Transl Sci       Date:  2015-07-14       Impact factor: 4.689

2.  Recruitment and retention monitoring: facilitating the mission of the National Institute of Neurological Disorders and Stroke (NINDS).

Authors:  J Roberts; S Waddy; P Kaufmann
Journal:  J Vasc Interv Neurol       Date:  2012-08

3.  Financial management of a large multisite randomized clinical trial.

Authors:  Alice J Sheffet; Linda Flaxman; MeeLee Tom; Susan E Hughes; Mary E Longbottom; Virginia J Howard; John R Marler; Thomas G Brott
Journal:  Int J Stroke       Date:  2014-03-24       Impact factor: 5.266

4.  Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI).

Authors:  Jenny L Donovan; Leila Rooshenas; Marcus Jepson; Daisy Elliott; Julia Wade; Kerry Avery; Nicola Mills; Caroline Wilson; Sangeetha Paramasivan; Jane M Blazeby
Journal:  Trials       Date:  2016-06-08       Impact factor: 2.279

Review 5.  A systematic review of training programmes for recruiters to randomised controlled trials.

Authors:  Daisy Townsend; Nicola Mills; Jelena Savović; Jenny L Donovan
Journal:  Trials       Date:  2015-09-28       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.